荃信生物(02509.HK)QX027N獲慢性阻塞性肺疾病及慢性鼻竇炎伴鼻息肉適應症臨床試驗默示許可

阿斯達克財經

08/03

荃信生物(02509.HK) 公布，近期，公司自主研發的長效雙抗QX027N注射液獲得中國國家藥品監督管理局藥品審評中心的臨床試驗默示許可，分別擬用於治療慢性阻塞性肺疾病(COPD)及慢性鼻竇炎伴鼻息肉(CRSwNP)。本次獲批是QX027N繼特應性皮炎(AD)及哮喘後新增的兩項呼吸系統相關適應症。(sl/u)(港股報價延遲最少十五分鐘。)AASTOCKS新聞

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2656143344"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2656143344\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2656143344?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240325152227966_s.jpg","is_english":false,"pubTime":"2026-08-03 10:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656143344","market":"fut","top_or_hot":-1,"title":"荃信生物(02509.HK)QX027N獲慢性阻塞性肺疾病及慢性鼻竇炎伴鼻息肉適應症臨床試驗默示許可","media":"阿斯達克財經","content":"<div>\n<p>荃信生物(02509.HK) 公布，近期，公司自主研發的長效雙抗QX027N注射液獲得中國國家藥品監督管理局藥品審評中心的臨床試驗默示許可，分別擬用於治療慢性阻塞性肺疾病(COPD)及慢性鼻竇炎伴鼻息肉(CRSwNP)。本次獲批是QX027N繼特應性皮炎(AD)及哮喘後新增的兩項呼吸系統相關適應症。(sl/u)(港股報價延遲最少十五分鐘。)AASTOCKS新聞</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1536161/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荃信生物(02509.HK)QX027N獲慢性阻塞性肺疾病及慢性鼻竇炎伴鼻息肉適應症臨床試驗默示許可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荃信生物(02509.HK)QX027N獲慢性阻塞性肺疾病及慢性鼻竇炎伴鼻息肉適應症臨床試驗默示許可\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2026-08-03 10:19</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>荃信生物(02509.HK) 公布，近期，公司自主研發的長效雙抗QX027N注射液獲得中國國家藥品監督管理局藥品審評中心的臨床試驗默示許可，分別擬用於治療慢性阻塞性肺疾病(COPD)及慢性鼻竇炎伴鼻息肉(CRSwNP)。本次獲批是QX027N繼特應性皮炎(AD)及哮喘後新增的兩項呼吸系統相關適應症。(sl/u)(港股報價延遲最少十五分鐘。)AASTOCKS新聞</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1536161/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1536161/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1536161/latest-news/AAFN","article_id":"2656143344","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240325152227966_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1536161/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2656143344","pubTimestamp":1785723540,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"荃信生物(02509.HK) 公布，近期，公司自主研發的長效雙抗QX027N注射液獲得中國國家藥品監督管理局藥品審評中心的臨床試驗默示許可，分別擬用於治療慢性阻塞性肺疾病(COPD)及慢性鼻竇炎伴鼻息肉(CRSwNP)。本次獲批是QX027N繼特應性皮炎(AD)及哮喘後新增的兩項呼吸系統相關適應症。(sl/u)(港股報價延遲最少十五分鐘。)AASTOCKS新聞","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02509":"荃信生物-B"},"translate_title":"Tsuen Xin Bio (02509.HK) QX027N obtained implied approval for clinical trial indications of chronic obstructive pulmonary disease and chronic sinusitis with nasal polyps","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1.5},"content_text":"荃信生物(02509.HK) 公布，近期，公司自主研發的長效雙抗QX027N注射液獲得中國國家藥品監督管理局藥品審評中心的臨床試驗默示許可，分別擬用於治療慢性阻塞性肺疾病(COPD)及慢性鼻竇炎伴鼻息肉(CRSwNP)。本次獲批是QX027N繼特應性皮炎(AD)及哮喘後新增的兩項呼吸系統相關適應症。(sl/u)(港股報價延遲最少十五分鐘。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}